Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Mantle cell lymphoma (MCL) remains an incurable disease with frequent relapses and no
standard therapeutic options in case of relapse. Prolongation of remissions or induction of
longer remissions is therefore crucial. Recently, a synergistic increase in the proteasomal
inhibition of ibrutinib in both bortezomib-sensitive and refractory MCL cells was shown.
These findings, along with the reported single agent activities of both drugs and the
non-overlapping toxicities, are the rationale to combine ibrutinib and bortezomib in MCL in
this trial